Dissertationen der Medizinischen Fakultät
Browse by Advisor: Herr, Prof. Dr. rer. nat. Ingrid
![[up]](/style/images/multi_up.png)
Up a level2022
An, Xuefeng (2022) α-Lipoic acid prevents side effects of therapeutic nanosilver without compromising cytotoxicity in pancreatic cancer.
Ji, Huihui (2022) Sulforaphane targets TRA-1/GLI upstream of DAF-16/FOXO to promote C. elegans longevity and healthspan.
Yan, Bin (2022) COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion.
2021
Bai, Liping (2021) Improved therapeutic effect of tumour treating fields upon combination with mild hyperthermia in pancreatic cancer.
Georgikou, Christina (2021) Inhibition of pancreatic cancer progression by sulforaphane-mediated downregulation of miR30a-3p and sulforaphane derivatives.
Luo, Yiqiao (2021) Sulforaphane inhibits the expression of long noncoding RNA H19 and thereby inhibits APOBEC3G-mediated pancreatic cancer progression.
Pfeifer, Tobias (2021) Mit elektrischen Wechselfeldern gegen Pankreaskrebs und Untersuchung der zugrundeliegenden Mechanismen.
2019
Xiao, Xi (2019) Evaluation of plant miRNA sequences from broccoli sprouts and putative cross-kingdom regulated human target gene.
Yin, Libo (2019) Evaluation of sulforaphane-induced microRNA signaling in progression of pancreatic cancer.
2018
Yin, Yefeng (2018) Simvastatin targets pancreatic cancer stem-like cells and sensitizes PDA cells to chemotherapeutic drugs via sonic hedgehog signaling.
2017
Bauer, Nathalie (2017) Development of a prognostic model for pancreatic cancer on fertilized chicken eggs.
Nwaeburu, Clifford C. (2017) Quercetin-induced microRNA regulation of Pancreatic Ductal Adenocarcinoma.
Zhao, Zhefu (2017) Establishment of a Personalized Treatment Model for Intraductal Papillary Mucinous Neoplasm of the Pancreas.
2016
Fan, Pei (2016) Analysis of therapy resistance after continuous treatment of pancreatic cancer cells with gemcitabine or bioactive agents.
2015
Isayev, Orkhan (2015) Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine.